Recherche
-
Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis
(Multiple Sclerosis and Related Disorders. vol. 57, pp. 103385, 2022-01)Article de revueLibre accès -
Differential vulnerability of thalamic nuclei in multiple sclerosis
(Multiple Sclerosis Journal, 2022-08-12)Article de revueLibre accès -
Improvements in quality of life over 2 years with cladribine tablets in people with relapsing multiple sclerosis: The CLARIFY-MS study
(Multiple Sclerosis Journal. vol. 29, n° 14, pp. 1808-1818, 2023-12)Article de revueLibre accès -
Untreated patients with multiple sclerosis: a study of French expert centers
(European Journal of Neurology. vol. 28, n° 6, pp. 2026-2036, 2021-06)Article de revueLibre accès -
Validation of the French version of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS)
(Multiple Sclerosis and Related Disorders. vol. 48, 2021-02)Article de revueLibre accès -
Prevalence, Severity, and Clinical Management of Brain Incidental Findings in Healthy Young Adults: MRi-Share Cross-Sectional Study
(Frontiers in Neurology. vol. 12, pp. 675244, 2021-05-20)Article de revueLibre accès -
Comparative effectiveness of dimethyl fumarate in multiple sclerosis
(British Journal of Clinical Pharmacology, 2021-03)Article de revueLibre accès -
Intra-database validation of case-identifying algorithms using reconstituted electronic health records from healthcare claims data
(BMC Medical Research Methodology. vol. 21, n° 1, pp. 95, 2021-05-01)Article de revueLibre accès